The Giant Papillary Conjunctivitis Market was valued at USD 0.5 billion in 2024 and is projected to reach USD 1.2 billion by 2034, registering a CAGR of 8.5%. This growth trajectory is underpinned by several factors, including the rising prevalence of allergic conjunctivitis, increasing awareness about eye health, and advancements in treatment options. The market is witnessing a surge in demand...